DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT07602803

Completed

The Effect of GLP1 Agonists on Weight Loss in BBS Cohort in the UK

GLP1 Agonists Once Weekly for the Treatment of Obesity in Patients With Bardet-Biedl Syndrome (BBS)

Asset

GLP-1 / incretin class catch-all

Listed sites

1

Recruiting sites

—

Enrollment

300

actual

Study population

Hypothalamic / syndromic obesity, Obesity / overweight

Key I/E criterion

—

Primary endpoint

•Weight loss change (%) at the end of study date

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07602803
Org study IDBBSGLP1

Timeline

Milestones

Study start2023-01-01actual
Primary completion2026-04-01actual
Study completion2026-04-22actual
Study first posted2026-05-22actual
Last update posted2026-05-27actual

Assets

Investigational agents

GLP-1 / incretin class catch-all

Study populations

Who this study enrolls

Hypothalamic / syndromic obesityObesity / overweight

Eligibility

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted
Sampling methodNon probability sample

Study population text

All the patients with a genetic diagnosis of BBS living in the UK under the UK National BBS Centres (Birmingham and London).

Inclusion criteria

•All the adult patients with a genetic diagnosis of BBS under the national BBS centres (London and Birmingham in the UK).

Exclusion criteria

•Adult patients with a genetic diagnosis of BBS under the national BBS centres (London and Birmingham in the UK) who lost follow ups or significant missing data, or BMI<30 in patients without GLP1 agonists.

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Weight & body composition

1 endpoint
Primary/protocol endpoint

Weight loss change (%) at the end of study date, compared to one at the time zero

Time frame:From enrolment to the end of treatment at the end of study date up to 18 months

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.